Drug information of Tirofiban


Tirofiban

Drug group:

Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

Mechanism of effect

Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.

Pharmacodynamic

When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy.

Pharmacokinetics

  • Half-life: 2 hr
  • Duration: 4 hr
  • Protein bound: 65%
  • Vd: 22-42 L
  • Clearance: 213-314 mL/min
  • Excretion: Urine (65%); feces (25%)
  • Dialyzable: Yes

Dosage

Adult

Non-ST Elevated Acute Coronary Syndrome

Loading dose: 25 mcg/kg IV infused within 5 min, THEN

Post loading dose infusion: 0.15 mcg/kg/min IV for up to 18 hr 

Pediatric

Safety and efficacy not established

Alerts

Platelets <150,000/cu.mm, hemorrhagic retinopathy, chronic HD

Points of recommendation

  • Have blood work checked as you have been told by the doctor. Talk with the doctor.
  • You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.
  • If you fall or hurt yourself, or if you hit your head, call your doctor right away. Talk with your doctor even if you feel fine.
  • Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using tirofiban while you are pregnant.

Pregnancy level

B

Related drugs

Eptifibatide , Ticlopidine , Abciximab


Ask a Pharmacist


سوالات کاربران
    No comments yet.